266 related articles for article (PubMed ID: 25496233)
21. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.
Rachner TD; Singh SK; Schoppet M; Benad P; Bornhäuser M; Ellenrieder V; Ebert R; Jakob F; Hofbauer LC
Cancer Lett; 2010 Jan; 287(1):109-16. PubMed ID: 19577359
[TBL] [Abstract][Full Text] [Related]
23. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of bisphosphonates on breast cancer cell lines.
Verdijk R; Franke HR; Wolbers F; Vermes I
Cancer Lett; 2007 Feb; 246(1-2):308-12. PubMed ID: 16621245
[TBL] [Abstract][Full Text] [Related]
25. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
26. Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
Suyama K; Noguchi Y; Tanaka T; Yoshida T; Shibata T; Saito Y; Tatsuno I
Oncol Rep; 2007 Nov; 18(5):1291-8. PubMed ID: 17914587
[TBL] [Abstract][Full Text] [Related]
27. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Fournier P; Boissier S; Filleur S; Guglielmi J; Cabon F; Colombel M; Clézardin P
Cancer Res; 2002 Nov; 62(22):6538-44. PubMed ID: 12438248
[TBL] [Abstract][Full Text] [Related]
31. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
Merrell MA; Wakchoure S; Ilvesaro JM; Zinn K; Gehrs B; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Mar; 559(1):21-31. PubMed ID: 17214981
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
34. Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.
Mitrofan LM; Castells FB; Pelkonen J; Mönkkönen J
J Biol Chem; 2010 Jan; 285(3):1967-79. PubMed ID: 19875454
[TBL] [Abstract][Full Text] [Related]
35. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
37. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
38. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.
Senaratne SG; Mansi JL; Colston KW
Br J Cancer; 2002 May; 86(9):1479-86. PubMed ID: 11986784
[TBL] [Abstract][Full Text] [Related]
39. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
[TBL] [Abstract][Full Text] [Related]
40. The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Mansouri M; Mirzaei SA; Lage H; Mousavi SS; Elahian F
Biochimie; 2014 Apr; 99():71-6. PubMed ID: 24287290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
